NDAORALCAPSULE
Approved
Feb 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
CLEOCIN HYDROCHLORIDE (clindamycin hydrochloride) by Pfizer is mechanism of action clindamycin inhibits bacterial protein synthesis by binding to the 23s rna of the 50s subunit of the ribosome. First approved in 1970.
Drug data last refreshed 54m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLEOCIN HYDROCHLORIDE (clindamycin HCl) is an oral capsule antibiotic approved in 1970 that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, making it bacteriostatic. It is used to treat bacterial infections across multiple indications. The drug represents a foundational lincosamide antibiotic with decades of clinical use and established safety data.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), signaling contraction in team size and shift toward defensive marketing and generic transition planning.
Mechanism of Action
Mechanism of Action Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Compound Adapalene and Clindamycin Hydrochloride Gel in Treatment of Patients With Acne
Started Mar 2015
245 enrolled
Acne
Career Relevance
Working on CLEOCIN offers career experience in late-lifecycle management, generic transition strategy, and established-product optimization rather than launch excitement. This role suits professionals interested in defensive business strategy, cost-containment tactics, and mature portfolio stewardship.
Generic Strategy Manager
Worked on CLEOCIN HYDROCHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.